Understanding quality of life in Danish women with metastatic breast cancer undergoing multiple treatments
DOI:
https://doi.org/10.2340/1651-226X.2025.42446Keywords:
Metastatic survivorship, patient reported outcome, breast cancer, more treatment linesAbstract
Background: Women with metastatic breast cancer (mBC) may experience several symptoms exacerbated by successive treatments. There is however, a lack of knowledge of the most important symptoms and how these may affect daily life function. This study aims to elucidate the quality of life (QoL), including both symptoms and daily life functions, among mBC women undergoing varied treatments.
Methodology: We conducted a cross-sectional electronic questionnaire study enrolling mBC women (≥ stage III) receiving medical cancer treatment through September–December 2023. QoL, symptoms, and daily life function were measured using the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) and the breast cancer module (BR45). Health-related quality of life (HRQoL), defined by the EORTC, covers the subjective perceptions of the positive and negative aspects of cancer patients’ symptoms, including physical, emotional, social, and cognitive functions. We examined associations between QoL, treatment line and therapy types, and estimated odds ratios (ORs) and confidence intervals (CIs).
Results: Of 359 eligible participants, 111 responded (30.9%). At study commencement, 90.9% of the participants received at least one type of systemic treatment, with 16.2% undergoing chemotherapy, 61.3% anti-hormonal treatment, and 66.6% targeted cancer treatment. QLQ-C30 sum scores were highest in women receiving anti-hormonal treatment (80.7, interquartile range [IQR]: 17.6), followed by targeted cancer treatment (78.8, IQR: 18.4), and lowest with chemotherapy (77.1, IQR: 24.8). Quality of life decreased with subsequent treatment lines (first line: 80.3, IQR: 20.7, fourth line: 67.4, IQR: 11.3). No significant differences were found in the functions or in the individual symptoms according to monotherapy type.
Interpretation: Women with mBC experience a substantial symptom burden and reduced functioning, and their QoL differs with successive lines of treatment. This underlines that women living with mBC need support and effective symptom management to maintain QoL.
Downloads
References
Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P, Danish Breast Cancer Cooperative Group. Improvements in breast cancer survival between 1995 and 2012 in Denark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55(Suppl 2):24–35.
https://doi.org/10.3109/0284186X.2015.1128119 DOI: https://doi.org/10.3109/0284186X.2015.1128119
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine thera-py at 5 years. N Engl J Med. 2017;377(19):1836–1846.
https://doi.org/10.1056/NEJMoa1701830 DOI: https://doi.org/10.1056/NEJMoa1701830
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer. 2020;129:60–70.
https://doi.org/10.1016/j.ejca.2020.01.016 DOI: https://doi.org/10.1016/j.ejca.2020.01.016
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.
https://doi.org/10.1016/j.annonc.2021.09.019 DOI: https://doi.org/10.1016/j.annonc.2021.09.019
DBCG [Internet]. [cited 2024 Oct 15] Available from: https://dbcg.dk/
Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10(10):1331–41.
https://doi.org/10.1001/jamaoncol.2024.3456 DOI: https://doi.org/10.1001/jamaoncol.2024.3456
Schmid P, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. Eur J Cancer. 2023;195:113393.
https://doi.org/10.1016/j.ejca.2023.113393 DOI: https://doi.org/10.1016/j.ejca.2023.113393
Ionescu Miron AI, Anghel AV, Antone-Iordache IL, Atasiei DI, Anghel CA, Barnonschi AA, et al. Assessing the impact of organ failure and metastases on quality of life in breast cancer patients: a prospective study based on utilizing EORTC QLQ-C30 and EORTC QLQ-BR45 Questionnaires in Romania. J Pers Med. 2024;14(2):214.
https://doi.org/10.3390/jpm14020214 DOI: https://doi.org/10.3390/jpm14020214
Brick RS, Gallicchio L, Mollica MA, Zaleta AK, Tonorezos ES, Jacobsen PB, et al. Survivorship concerns among individuals diagnosed with metastatic cancer: findings from the Cancer Experience Registry. J Cancer Surviv. 2024; epub ahead of print.
https://doi.org/10.1007/s11764-024-01573-8 DOI: https://doi.org/10.1007/s11764-024-01573-8
Fayers P, Bottomley A, EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38(Suppl 4):S125–33.
https://doi.org/10.1016/S0959-8049(01)00448-8 DOI: https://doi.org/10.1016/S0959-8049(01)00448-8
Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, et al. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer. 2020;125:69–82.
https://doi.org/10.1016/j.ejca.2019.10.031 DOI: https://doi.org/10.1016/j.ejca.2019.10.031
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.
https://doi.org/10.1200/JCO.1996.14.10.2756 DOI: https://doi.org/10.1200/JCO.1996.14.10.2756
Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, et al. An international update of the EORTC questionnaire for as-sessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020;31(2):283–8.
https://doi.org/10.1016/j.annonc.2019.10.027 DOI: https://doi.org/10.1016/j.annonc.2019.10.027
Smith AL, Hart NH, Jefford M, Chan RJ. Survivorship research for people with metastatic or advanced cancer: a time for action. Asia Pac J Oncol Nurs. 2022;9(4):185–6.
https://doi.org/10.1016/j.apjon.2022.02.001 DOI: https://doi.org/10.1016/j.apjon.2022.02.001
Mollica MA, Smith AW, Tonorezos E, Castro K, Filipski KK, Guida J, et al. Survivorship for individuals living with advanced and metastatic cancers: National Cancer Institute Meeting Report. J Natl Cancer Inst. 2022;114(4):489–95.
https://doi.org/10.1093/jnci/djab223 DOI: https://doi.org/10.1093/jnci/djab223
Kida K, Olver I, Yennu S, Tripathy D, Ueno NT. Optimal supportive care for patients with metastatic breast cancer according to their disease progression phase. JCO Oncol Pract. 2021;17(4):177–83.
https://doi.org/10.1200/OP.20.00622 DOI: https://doi.org/10.1200/OP.20.00622
Lustberg MB, Carlson M, Nekhlyudov L. Introduction to special section: living with Incurable Cancer: Addressing Gaps in Cancer Survivor-ship. J Cancer Surviv. 2021;15(3):367–9.
https://doi.org/10.1007/s11764-021-01047-1 DOI: https://doi.org/10.1007/s11764-021-01047-1
The Danish Breast Cancer Group D. Systemic treatment of breast cancer [Systemisk behandling af brystkræft III – palliativ og systemisk behandling af metastaserende brystkræft (MBC)] [Internet]. The Danish Breast Cancer Group (DBCG); 2024 [cited 2025 Jan 22]. Available from: https://www.dmcg.dk/siteassets/retningslinjer/godkendte-kr/dbcg/dbcg_pall-syste-bh-mbc_v.2.1_admgodk_211024.pdf
E-boks [Internet]. [cited 2024 Oct 22]. Available from: https://global.e-boks.com/why-e-boks/
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Stud-ies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.
https://doi.org/10.1016/S0140-6736(07)61602-X DOI: https://doi.org/10.1016/S0140-6736(07)61602-X
Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31–4.
https://doi.org/10.4103/sja.SJA_543_18 DOI: https://doi.org/10.4103/sja.SJA_543_18
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
https://doi.org/10.1016/j.jbi.2019.103208 DOI: https://doi.org/10.1016/j.jbi.2019.103208
European Organization for Research and Treatment of Cancer. EORTC QoL group [Internet]. [cited 2024 Oct 24]. Available from: https://qol.eortc.org/
FFayers P. EORTC QLQ-C30 Scoring Manual [Internet]. European Organisation for Research and Treatment of Cancer; 2001 [cited 2024 Aug 1]. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
Young T, Velikova G, Liegl G, Rose M, Nolte S, EORTC Quality of Life Group. EORTC QLQ-C30 normative data for the United Kingdom: results of a cross-sectional survey of the general population. Eur J Cancer. 2024;204:113927.
https://doi.org/10.1016/j.ejca.2024.113927 DOI: https://doi.org/10.1016/j.ejca.2024.113927
Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019;107:153–63.
https://doi.org/10.1016/j.ejca.2018.11.024 DOI: https://doi.org/10.1016/j.ejca.2018.11.024
Juul T, Petersen MA, Holzner B, Laurberg S, Christensen P, Grønvold M. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res. 2014;23(8):2183–93.
https://doi.org/10.1007/s11136-014-0675-y DOI: https://doi.org/10.1007/s11136-014-0675-y
Tommasi C, Balsano R, Corianò M, Pellegrino B, Saba G, Bardanzellu F, et al. Long-term effects of breast cancer therapy and care: calm after the storm? J Clin Med. 2022;11(23):7239.
https://doi.org/10.3390/jcm11237239 DOI: https://doi.org/10.3390/jcm11237239
Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12(12):1443–55.
https://doi.org/10.1634/theoncologist.12-12-1443 DOI: https://doi.org/10.1634/theoncologist.12-12-1443
Sodergren SC, Copson E, White A, Efficace F, Sprangers M, Fitzsimmons D, et al. Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on Behalf of the EORTC Quality of Life Group. Target Oncol. 2016;11(3):277–92.
https://doi.org/10.1007/s11523-015-0409-2 DOI: https://doi.org/10.1007/s11523-015-0409-2
Curran D, Aaronson N, Standaert B, Molenberghs G, Therasse P, Ramirez A, et al. Summary measures and statistics in the analysis of quali-ty of life data: an example from an EORTC–NCIC–SAKK locally advanced breast cancer study. Eur J Cancer. 2000;36(7):834–44.
https://doi.org/10.1016/S0959-8049(00)00056-3 DOI: https://doi.org/10.1016/S0959-8049(00)00056-3
Puetzler J, Feldmann Jr. RE, Brascher AK, Gerhardt A, Benrath J. Improvements in Health-related quality of life by comprehensive cancer pain therapy: a pilot study with breast cancer outpatients under palliative chemotherapy. Oncol Res Treat. 2014;37(9):456–62.
https://doi.org/10.1159/000365537 DOI: https://doi.org/10.1159/000365537
Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol. 2012;29(2):432–8.
https://doi.org/10.1007/s12032-011-9844-9 DOI: https://doi.org/10.1007/s12032-011-9844-9
Twelves CJ, Miles DW, Hall A. Quality of life in women with advanced breast cancer treated with docetaxel. Clin Breast Cancer. 2004;5(3):216–22.
https://doi.org/10.3816/CBC.2004.n.025 DOI: https://doi.org/10.3816/CBC.2004.n.025
Wallwiener M, Simoes E, Sokolov A, Brucker S, Fasching P, Graf J. Health-related quality of life in metastatic and adjuvant breast cancer patients. Geburtshilfe Frauenheilkd. 2016;76(10):1065–73.
https://doi.org/10.1055/s-0042-113188 DOI: https://doi.org/10.1055/s-0042-113188
Lai-Kwon J, Khoo C, Lo S, Milne D, Mohamed M, Raleigh J, et al. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv. 2019;13(4):503–11.
https://doi.org/10.1007/s11764-019-00770-0 DOI: https://doi.org/10.1007/s11764-019-00770-0
Hart NH, Nekhlyudov L, Smith TJ, Yee J, Fitch MI, Crawford GB, et al. Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations. JCO Oncol Pract. 2024;20(9):1160–72.
https://doi.org/10.1200/OP.23.00716 DOI: https://doi.org/10.1200/OP.23.00716
Rodin G, Lo C, Rydall A, Shnall J, Malfitano C, Chiu A, et al. Managing cancer and living meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol. 2018;36(23):2422–32.
https://doi.org/10.1200/JCO.2017.77.1097 DOI: https://doi.org/10.1200/JCO.2017.77.1097
Grassi L, Zachariae R, Caruso R, Palagini L, Campos-Ródenas R, Riba MB, et al. Insomnia in adult patients with cancer: ESMO clinical practice guideline. ESMO Open. 2023;8(6):102047.
https://doi.org/10.1016/j.esmoop.2023.102047 DOI: https://doi.org/10.1016/j.esmoop.2023.102047
Bower JE, Lacchetti C, Alici Y, Barton DL, Bruner D, Canin BE, et al. Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. J Clin Oncol. 2024;42(20):2456–87.
https://doi.org/10.1200/JCO.24.00541 DOI: https://doi.org/10.1200/JCO.24.00541
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Helle Pappot, Annasofie Jørgensen, Anna Hincheli Bjørum, Christina Bøgh Jakobsen, Camilla Uhre Jørgensen, Beverley Lim Høeg, Pernille Bidstrup, Ann Knop, Line Bentsen
This work is licensed under a Creative Commons Attribution 4.0 International License.
